Common Type Of Hair Loss Research Articles

Assessing the efficacy and quality of Life improvements of botulinum toxin type a with topical minoxidil versus topical minoxidil in male androgenetic alopecia: a randomized controlled trial.

Androgenetic alopecia (AGA) is a common type of hair loss in men and efficacy and safety of current medical treatment remain limited. Therefore, the present study aimed to investigate the efficacy and safety of botulinum toxin type A (BTA) combined with Minoxidil in patients with AGA. 60 male patients were included in this study and control group received topical 5% Minoxidil and the treatment group received BTA combined with topical 5% Minoxidil. BTA injections (60-70 U) were administered at 30-35 scalp sites. Head photographs were taken at baseline, 2nd, 4th, and 6th months. Clinical descriptions recorded scalp conditions, and patient satisfaction along with Dermatology Life Quality Index scores were documented. The treatment group (TG) showed significant hair growth differences compared to the control group (CG) at the 4th month (P < 0.001) and 6th month (P = 0.0046) post-treatment. TG had improved Investigator Global Assessment (IGA) scores in the 4th month (P = 0.0001) and 6th month (P = 0.0259) compared to CG. Patient satisfaction in TG for hair growth and scalp improvement was higher than CG (all P < 0.05). TG exhibited substantial quality of life improvement at the 4-month (P = 0.0009) and 6-month (P = 0.0099). No adverse reactions were observed post-botulinum toxin injection. BTA combined with Minoxidil effectively promotes hair growth, enhances the quality of life, and alleviates scalp symptoms in male AGA patients at 4th and 6th months, with no adverse effects compared to Minoxidil alone.Trial registration number: Ethics Committee of Shanghai Tongji Hospital (ID: K-2018-026).

The latest reports on androgenetic alopecia

Androgenetic alopecia (AGA) is the most common type of hair loss among women and men.AGA is caused by a combination of genetic factors resulting in sensitivity to dihydrotestosterone (DHT), which binds to the androgen receptor (AR), mediating a series of biomolecular changes that lead to changes in the hair. There are many mechanisms that can lead to AGA, some of which remain undiscovered. Treatment of AGA is also important for psychological reasons, as it constitutes a significant psychosocial stressor in the lives of people affected by this disease and worsens the quality of life. The only medications approved for the treatment of AGA are oral finasteride and topical minoxidil. These drugs may be associated with side effects, hence the need to look for other treatment methods, especially for patients who cannot tolerate approved methods. The current review focuses on the latest reports on the pathogenesis and treatment of androgenetic alopecia.

Patient-Based Ratio Method for Permanent Zone Donor Area Calculation in Hair Transplant

Abstract Introduction Most common type of hair loss is androgenetic alopecia. Orentreich's donor dominance theory and the definition of safe donor area are the theoretical foundation of modern hair transplantation. In safe donor area no progression of permanent hair loss occurs. Its knowledge is important to prevent loss of transplanted hair. Estimation is not tailored to every patient, also in early stages, the margins are assumed to be free from future hair loss. Our study is an attempt to find and establish a relationship between safe zone dimensions and other standard scalp dimensions, and effectively predict the complete safe zone in early stages of hair loss. Materials and Methods From July to December 2022, the first 100 patients with Norwood IV onwards of hair loss were included. Then, the distance between the vertex and the point of change in occipital hair quality and density was measured, and from this point till occipital protuberance were taken. The ratio between the two was taken. In the next 100 patients of Norwood II to IVa, the applicability of the new ratio to assess the permanent zone was used. Results Ratio method takes into account the patient's measurements, that is, permanent zone and total distance from vertex occiput. The ratio range we got is:Permanent zone: total distance from vertex to occiput: 0.43–0.53Therefore, the permanent zone would be equal to = total distance from vertex to occiput × 0.43–0.53. With the lower limit being the occiput. Over 90% of the patients did not have significant reduction in density of transplanted hair. Conclusion The authors suggest the use of this ratio method to determine the dimensions of the permanent zone especially in patients with early grades of hair loss as per the Norwood scale. It is a simple, effective, and easily applicable concept that can ensure long-lasting results in patients undergoing hair transplants.

Efficacy of Platelet-Rich Plasma versus Mesotherapy with Recombinant Growth Factors and Stem Cell-Conditioned Media in Androgenetic Alopecia: A Retrospective Study

Introduction: Androgenetic alopecia (AGA) is the most common type of hair loss. Platelet-rich plasma (PRP) and mesotherapy (MZT) injections of various solutions fortified with growth factors are popular treatment options for AGA. The aim of this study was to compare the efficacy of RPP and MZT products in the treatment of AGA. Methods: This retrospective study included 72 AGA patients treated with two PRP formulations and two MZT products, administered manually or with a gun injector. Hair parameters (hair thickness, hair density, and hair count) on frontal and vertex areas were measured before and after 6 months. Results: Over 6 months, trichoscopic parameters showed significant intragroup and intergroup variability. MZT1 and PRP2 groups exhibited statistically significant improvement in most parameters, while MZT2 significantly increased vertex hair density. Hair thickness changes differed significantly between PRP1 and PRP2 groups (unadjusted p value <0.001) and possibly between MZT1 and PRP1 groups (unadjusted p value = 0.049) in both regions. Discussion: Injections of PRP and MZT formulations can significantly enhance trichoscopic parameters in AGA patients within a 6-month period, but the extent of improvement varies among different PRP and MZT products.

The 100 Most Cited Androgenetic Alopecia Articles: An Analysis of Altmetrics Data from 2015 to 2022

Introduction: Androgenetic alopecia is the most common type of hair loss, and with increasing media integration in medicine, understanding social media consumption of literature is invaluable. Altmetric Attention Score analysis can quantify factors impacting article distribution on media platforms. Methods: To determine factors influencing literature dissemination and reader demographics, a bibliometric analysis was performed on the 100 most cited androgenetic alopecia articles. Results: Articles with top 25th percentile Altmetric Attention Scores were cited more frequently (41.76 vs. 24.59, p < 0.05). Open-access articles had lower odds of being read by healthcare professionals (aOR = 0.16, p < 0.05), while funded studies and journal impact factor increased odds of readership (aOR = 5.80; aOR = 1.55; p < 0.05 for both). Scientists and healthcare professionals showed interest in publications addressing 5α-reductase inhibitors (aOR = 26.08; aOR = 6.13; p < 0.05 for both). Articles with high social media viewership were also highly cited in academic literature. Conclusion: Healthcare professionals appeared more discerning about article readership compared to the public. With many outlets for consumption of media, members of the public not involved in dermatology may have difficulty in identifying reliable sources of material. Overall, Altmetrics can help quantify readership trends and public interest in dermatology research.

Multifunctional ionic liquids-mediated topical delivery of minoxidil and EGCG for treating androgenic alopecia through promoting angiogenesis and scavenging ROS

Androgenic alopecia (AGA) is the most common type of hair loss, causing serious physical and mental distress to patients. The key factors contributing to AGA include oxidative stress and insufficient vascularization in the microenvironment around hair follicles. Currently, the available treatment options are limited, and there is no comprehensive treatment strategy with minimal side effects and optimal efficacy. Herein, we developed a novel minoxidil and epigallocatechin gallate co-loaded ionic liquids drug delivery system (ME@CGIL), which was simple to prepare and could effectively regulate hair follicle microenvironment homeostasis. After topical application, the ionic liquids, which had a certain function of promoting hair regrowth, facilitated drugs delivery into the epidermis and dermis while prolonging their retention time, so as to reduce the frequency and dosage requirements. ME@CGIL promoted hair regrowth by activating hair follicle stem cells, scavenging excessive reactive oxygen species and promoting neovascularization in the AGA mouse model, showing superior efficacy than commercially available minoxidil products. Altogether, this study may provide a simple and ingenious treatment strategy for AGA, which has great potential for clinical application.

The Current Status of Seborrheic Alopecia in Young People and Its Correlation with Fungal Infections

The current status of seborrheic alopecia (SA) in young people and its potential association with fungal infections was discussed. Pathological representations, pathogenesis and therapeutic strategies of seborrheic alopecia were introduced. SA is the most common type of hair loss in adults, but it also occurs in adolescents, though its prevalence among this younger population is not well established. Skin biocenosis, in particular the Malassezia spp. flora, plays a key aetiologic role, in combination with the unusual capacity of some corneocytes to be coated by these yeasts.

Characterization of distinct microbiota associated with androgenetic alopecia patients treated and untreated with platelet-rich plasma (PRP).

Androgenic alopecia (AGA) is the most common type of hair loss in men, and there are many studies on the treatment of hair loss by platelet-rich plasma (PRP). The human scalp contains a huge microbiome, but its role in the process of hair loss remains unclear, and the relationship between PRP and the microbiome needs further study. Therefore, the purpose of this study was to investigate the effect of PRP treatment on scalp microbiota composition. We performed PRP treatment on 14 patients with AGA, observed their clinical efficacy, and collected scalp swab samples before and after treatment. The scalp microflora of AGA patients before and after treatment was characterized by amplifying the V3-V4 region of the 16 s RNA gene and sequencing for bacterial identification. The results showed that PRP was effective in the treatment of AGA patients, and the hair growth increased significantly. The results of relative abundance analysis of microbiota showed that after treatment, g_Cutibacterium increased and g_Staphylococcus decreased, which played a stable role in scalp microbiota. In addition, g_Lawsonella decreased, indicating that the scalp oil production decreased after treatment. The findings suggest that PRP may play a role in treating AGA through scalp microbiome rebalancing.

Effectiveness and safety of the combination therapy of micro-needling and minoxidil in androgenetic alopecia of Indonesian men: a randomized controlled trial

Introduction: Androgenetic alopecia (AGA) is the most common type of hair loss. Treatment options are limited. Microneedling, a minimally invasive technique can enhance hair growth by releasing growth factors. However, standardized protocol regarding the frequency, depth and duration has not been available. This study aims to determine the effectiveness and safety of the combination therapy of microneedling and minoxidil in AGA. Methods: This study was a randomized controlled clinical trial conducted over 12 weeks. Intervention group: a combination therapy of 4-weekly microneedling and 5% minoxidil, and control group got topical 5% minoxidil alone. Hair density and diameter were assessed using FotoFinder® trichoscale every 4 weeks. Results: A total of 36 male participants, between 26-51 years old, with Hamilton-Norwood type III-VI AGA were included. At the end of study, a significant increase in hair density was observed in the intervention group compared to control (95.6 vs 52.4 hair/cm², p&lt;0.001), as was in hair diameter (18 vs 6 μm, p=0.004). Side effects, included itching and transient erythema, were well tolerated. Conclusion: The combination of 4-weekly microneedling and topical 5% minoxidil is effective in increasing both hair density and hair diameter, and safe to use in AGA patients.

Medical Treatment for Androgenetic Alopecia.

Androgenetic alopecia is a common type of hair loss, which is generally influenced by genetic factors and systemic androgens resulting in follicular miniaturization.1 It can cause cosmetic problems leading to psychological distress among affected men and women. Effective standard medical treatments available are topical minoxidil 2 to 5%, oral finasteride, oral dutasteride, and hair transplantation.1 However, some patients do not achieve favorable results with standard treatments. For these reasons, other novel treatments have been developed, including new medications, regenerative medicines (autologous platelet-rich plasma, adipose-derived stem cells, micrograft generation, and exosome), and low-level laser therapy.

Medicinal and cosmetic products used in treatment of hair loss

Abstract Hair loss or alopecia is a reduction in the volume or complete loss of hair and is a fairly common clinical problem, especially in the geriatric population. Androgenetic alopecia (AGA) is the most common type of hair loss in men. Androgenetic alopecia in women most often occurs before the age of 60. We also distinguish androgenetic alopecia in postmenopausal women and scarring, areata, telogen and drug-induced alopecia. The aim of the study was to analyze the composition of medicinal and cosmetic preparations available on the Polish market, recommended for people struggling with alopecia. In 2022, the composition of preparations used in alopecia available in pharmacies and drugstores was analyzed. In total 57 medicinal and cosmetic preparations recommended for people suffering from alopecia have been identified. The most common active substance in the analyzed preparations is finasteride. Frequently used active substances are biotin and minoxidil, rarely prednisolone. Conclusions: 1. In preparations intended for people with alopecia, the most frequently used active substance is finasteride. 2. Statistically, preparations for hair loss are most often in the form of tablets and shampoos. 3. The analyzed preparations for alopecia belong to the category of prescription drugs and cosmetics, less often in the category of OTC drugs or dietary supplements.

Hair Transplantation in the United States: A Population-based Survey of Female and Male Pattern Baldness

Background: Androgenetic alopecia, the most common type of hair loss, can impair the patient’s overall mental health. Although there are pharmaceutical and surgical treatments available, little is known about the public standpoint toward hair transplantation (HT). Methods: A sample of individuals living in the United States (n = 1000; male and female participants were equally distributed) was asked to fill out the questionnaire. The online survey was conducted in June 2022. Results: Most participants (42%; n = 416) were between 41 and 60 years of age. Study participants frequently reported that, with their hair loss progressing, they would not feel attractive anymore (n = 400; 40%), nor as confident as before (n = 330; 33%). Although women with minimal hair loss were willing to spend a median price of $4000 [interquartile range (IQ) IQR $1000–$5000], women with extensive hair loss were willing to spend significantly more (median = $5000; IQR $3600–$6375; P = 0.011). This was reproducible in men (P = 0.033). Although significantly fewer women considered undergoing HT (430 women versus 447 men; P &lt; 0.001), female participants were willing to pay more for their HT compared with men (P = 0.039). Conclusions: Individuals living in the United States consider hair loss to impair their attractiveness and regard HT as a valuable therapeutic option. More affordable and gender-specific HT should be subject to future research work.

Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: a systematic review and meta-analysis.

Androgenetic alopecia is a widespread condition that is the most common type of hair loss affecting approximately 58% and 40% of men and women by the age of 50, respectively. Patients have been known to experience severe distress due to androgenetic alopecia, including anxiety, low self-esteem, and depression. The objective of this study was to conduct a systematic review and meta-analysis to determine the efficacy of combination therapy using topical minoxidil and microneedling compared to topical minoxidil alone. This systematic review of randomized controlled trials was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. The literature search was performed using Scopus, Cochrane, Embase, and the National Institutes of Health's United States National Library of Medicine from inception through January 20, 2023. Randomized controlled trials examining the efficacy of combinational therapy and monotherapy using microneedling and minoxidil on patients with clinically diagnosed androgenetic alopecia were included after screening titles, abstracts, and full texts. Two independent reviewers selected studies, extracted data, and appraised the risk of bias using the Cochrane risk of bias assessment tool. Ten randomized controlled trials, including 466 patients, were selected for this review and eight studies were ultimately included in the meta-analysis. All eight studies displayed a statistically significant increase in total hair count [standard mean difference (SMD) 1.76; 95% CI 1.26-2.26; P < 0.00001]; however, the evidence did not support a statistically significant increase in hair diameter (SMD 0.82; 95% CI -0.01 to 1.65; P = 0.05). No scarring nor serious adverse events were reported in any of the studies. The findings of this meta-analysis strongly support the utilization of a multimodal therapeutic approach of minoxidil and microneedling for hair growth in patients with androgenetic alopecia. However, variations in factors such as rating scale measurements, microneedling methods, and areas of treatment may have resulted in confounding. Further randomized controlled, large-sample trials employing rigorous methodologies are needed to gain a more comprehensive understanding regarding treatment efficacy, namely the impact of combinational therapy on hair diameter.Clinical trial registrations This study follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and is registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (CRD42023391164) and the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY) database (INPLASY202310031).

Female Pattern Hair Loss and Negative Psychological Impact: Possible Role of Brain-derived Neurotrophic Factor (BDNF).

Female Pattern Hair Loss (FPHL) is considered the most common type of hair loss in females. Women with FPHL may suffer from psychological distress and defective social functioning. Patients with psychiatric and neurodegenerative disorders almost have a deficient brain and blood brain-derived neurotrophic factor levels (BDNF). This serum BDNF level may act as a diagnostic marker for negative psychological impact in FPHL patients. Evaluate the levels of serum BDNF in patients with FPHL and correlate its level to the severity of alopecia and the degree of psychological impact. Forty-six female patients with FPHL and 41 healthy age-matched female volunteers as a control were included in the study. Patients filled out a Dermatology Life Quality Index questionnaire. Both patients and controls filled Beck Depression Inventory, Beck Anxiety Inventory, and Perceived Stress Scale (PSS) questionnaires. Serum levels of BDNF were measured for all the participants using the ELISA technique. Patients with FPHL had significantly lower levels of BDNF and significantly higher Beck depression inventory score and PSS questionnaire scores. There is a significant negative correlation between serum levels of BDNF and Beck Depression Inventory, Beck Anxiety Inventory, and PSS questionnaire scores. Patients with FPHL are at a high risk to develop chronic stress and depression. The serum level of BDNF is a good predictor for the assessment of chronic stress and depression in FPHL patients.

Effects of photobiomodulation at various irradiances on normal and dihydrotestosterone-treated human hair dermal papilla cells in vitro.

Androgenetic alopecia (AGA) is the most common type of hair loss caused by dihydrotestosterone (DHT) binding to androgen receptors in dermal papilla cells (DPCs). Photobiomodulation (PBM) is a promising treatment for AGA but suffers from inconsistent outcomes and inconsistent effective light parameters. This study investigated the impact of red light at various irradiances on normal and DHT-treated DPCs. Our results suggested that red light at 8 mW/cm2 was most effective in promoting DPCs growth. Furthermore, a range of irradiances from 2 to 64 mW/cm2 modulated key signaling pathways, including Wnt, FGF, and TGF, in normal and DHT-treated DPCs. Interestingly, 8 mW/cm2 had a greater impact on these pathways in DHT-treated DPCs and altered the Shh pathway, suggesting that the effect of PBM varies with the cellular environment. This study highlights specific factors that influence PBM effectiveness and provides insight into the need for personalized PBM treatment approaches.

Non-surgical treatments for androgenetic alopecia: a literature review

Androgenetic alopecia is the most common type of hair loss and affects at least 80% of men and half of women before the age of 70, with the incidence increasing with age. Androgenetic alopecia is an ailment conditioned by genetic and hormonal factors, associated with excessive stimulation of the androgen receptor in the cells of the hair follicle. With the development of medicine, more and more therapeutic methods for androgenetic alopecia appear on the market, including minoxidil, 5-α-reductase inhibitors, microneedling, platelet-rich plasma, low-energy laser therapy, rosemary oil, or siRNA. Thanks to the constantly growing amount of scientific research, progressively more is known about the mechanisms of androgenetic alopecia development and potential strategies to stop it. The article analyzes the literature using electronic databases and textbooks to compile methods that can be an effective alternative for people who do not want to undergo surgery. Some of the methods presented in the article have the potential to not only slow down, but also reverse the progression of the disease. However, each of them still has its limitations.

Female Pattern Hair Loss: An Overview with Focus on the Genetics.

Pattern hair loss can occur in both men and women, and the underlying molecular mechanisms have been continuously studied in recent years. Male androgenetic alopecia (M-AGA), also termed male pattern hair loss, is the most common type of hair loss in men. M-AGA is considered an androgen-dependent trait with a background of genetic predisposition. The interplay between genetic and non-genetic factors leads to the phenotype of follicular miniaturization. Although this similar pattern of phenotypic miniaturization can also be found in female pattern hair loss (FPHL), the corresponding genetic factors in M-AGA do not account for the phenotype in FPHL, indicating that there are different genes contributing to FPHL. Therefore, the role of genetic factors in FPHL is still uncertain. Understanding the genetic mechanism that causes FPHL is crucial for the future development of personalized treatment strategies. This review aims to highlight the differences in the ethnic prevalence and genetic background of FPHL, as well as the current genetic research progress in nutrition, Wnt signaling, and sex hormones related to FPHL.

Effects Of Smoking On Hair Loss

Hair loss, also known as alopecia can be caused by avariety of factors like hormonal changes, medicalconditions, medications, nutritional deficiency stressand also smoking .The underlying biological mechanismthat may link smoking to hair loss are not yet fullyunderstood, but it is thought that smoking has anegative impact on blood supply to hair follicles.Significant association between smokers having ahigher risk of developing hair loss compared to nonsmokers. Furthermore the study also shows a positivecorrelation between smoking and male pattern baldnesswhich is a common type of hair loss in men. Themanagement and prevention of hair loss fromsmoking require various level of intervention. Individuallevel intervention like abstaining from smoking,increasing awareness among youth regarding theeffects of smoking. Similar recommendations on thecommunity level and country level like bandingcigarettes, taxation of tobacco products, smokingcessation program like camping and nicotinereplacement therapy.

Experience of Novelty Laser Therapy Emission with 675 nm Wavelength for the Treatment of Androgenetic Alopecia in Male and Female Patients: A Case Series Study.

Background: Alopecia androgenetica is the most common type of hair loss. It is estimated that 60-70% of the world's population is affected, with men having a slight advantage. This condition supports a progressive hair thinning in androgen-sensitive zones, as defined by the Hamilton and Norwood classifications for men and Ludwig classifications for women. There are numerous published studies that show the effect of red light (650-675 nm) on hair growth biostimulation. Objective: To validate this correlation, the aim of this study was to assess the efficacy of 675 nm laser emission for the management of alopecia androgenetica in female and male subjects. Methods: A total of 17 subjects (6 women and 11 men) aged from 18 to 65 years, without other comorbidities, with an alopecia androgenetica grade ranges between I-II in women (according to Ludvig scale) and I-II-III in men (according to Hamilton scale) were enrolled in the study between October and December 2021. All patients underwent 10 sessions of 675 nm laser treatment, each lasting 20 min, without the use of concomitant systemic or topical therapies. Results: The results verified at epiluminescence stage, and at the third month of follow-up and at the end of treatment, showed a significant increase in the density of the hair shafts and a reduction of yellow dots and telangiectasias characteristic of alopecia androgenetica. Conclusions: The 675 nm laser showed excellent outcomes resulting in a 60% reduction of the miniaturization process in the treated areas without side effect.

The Progress of Common Treatments and Research for Androgenetic Alopecia

Androgenetic alopecia (AGA) is the most common type of hair loss, in which patients mostly present with a state of a receding hairline on the forehead. It brings a great mental burden to the patient. Androgenetic alopecia is caused by the combination of dihydrotestosterone (DHT) and androgen receptors (AR), disrupting the hair follicle cycle and minimizing hair follicles. The major treatments currently available include finasteride, minoxidil, hair transplantation, Platelet-rich plasma (PRP), stem cell therapy, etc. This article reviews the mechanism of AGA and the existing major treatments. The author suggested that androgen receptor degrader drugs have good prospects for application among those of various therapeutic options.